Indian Pharma market to bloom with 10-12 pc growth in FY 2019-20: CLSA

New Delhi, July 16 (HS): According to report of Credit Lyonnais Securities Asia (CLSA) investment group based out of Hong Kong, Indian Pharma market is set to grow at 1- to 12 pc in this financial year of 2019-20. The various pharma companies in India have consistently outperformed stock market recently. Besides this, they have expanded their portfolio of products and market across border. There has been growth of 14.4 pc yearly  in chronic segments including anti-diabetic and 9 pc yearly in acute segment.

This report also reveals that Cipla is the slowest growing company and Dr. Reddy’s Laboratories is the fastest growing company, while other companies like Lupin and Glenmark are in good space to grow.  The revenues of Dr. Reddy’s Laboratories have shown upward trend with 13.9 percent yearly growth. Its top brands have also registered double digit growth while Cipla has reported declines in sales of its products leading to nominal growth.